Methylene blue as vasopressor in septic shock
Not Applicable
- Conditions
- Health Condition 1: I958- Other hypotension
- Registration Number
- CTRI/2021/02/031514
- Lead Sponsor
- Institute of Medical Sciences BH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Age group between 18-65 years.
2.Patients fulfilling the above criteria for septic shock (Sepsis-3 definition)
3.Patients who required Noradrenaline support of >= 0.2 µg/kg/min to maintain MAP of 65-70 mm Hg.
Exclusion Criteria
1. Patient refusal.
2. Patients who were pregnant
3. Patients with known sensitivity to Methylene Blue.
4. Patient age less than 18 years.
5. Patients with known H/O G6PD disease, valvular heart disease, present or suspected coronary heart disease, and present or suspected acute mesenteric ischemia or vasoplastic diathesis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To Determine whether Methylene Blue will decrease 28-Days mortality, as compared with Vasopressin in patients of septic shock who are on high dose Noradrenaline IV infusion (� 0.2 µg/kg/min).Timepoint: 24 hours
- Secondary Outcome Measures
Name Time Method TO Determine beneficial effects of Methylene Blue over Vasopressin in terms of duration of shock and more vasopressor requirements.Timepoint: 24 hours